89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo

Journal of Nuclear Medicine

Volumn 51, Issue 8, 2010, Pages 1293-1300

  Holland, Jason P ^a   Divilov, Vadim ^a   Bander, Neil H ^a,b   Smith Jones, Peter M ^a   Larson, StevenM ^a   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

89Zr; Density functional theory; ImmunoPET; J591; Monoclonal antibodies; Prostate specific membrane antigen (PSMA)

Indexed keywords

CHLORIDE ZR 89; DESFERRIOXAMINE B ZR 89; MONOCLONAL ANTIBODY; OXALATE ZR 89; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; DIAGNOSTIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY J591;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DENSITY FUNCTIONAL THEORY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CHEMICAL STRUCTURE; IMMUNOLOGY; NUDE MOUSE; STATISTICAL ANALYSIS; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; DATA INTERPRETATION, STATISTICAL; DRUG STABILITY; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; MALE; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 77956193105     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.076174     Document Type: Article

References (36)

1. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031-2041.
2. Olson WC, Heston WDW, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2:182-190.
3. Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med. 2005;46(1 suppl):141S-150S.
4. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. 2000;43:150-157.
5. Manyak MJ. Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther. 2008;8:175-181.
6. Morris MJ, Pandit-Taskar N, Divgi CR, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res. 2007;13:2707-2713.
7. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor endothelium. Cancer Res. 1997;57:3629-3634.
8. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998; 58:4055-4060. (Pubitemid 28440554)
9. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237-5243.
10. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med. 2003;44:610-617.
11. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095-6100.
12. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate. 2004;58:145-155.
13. 177Lu? J Nucl Med. 2005;46:634-641.
14. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717-1721.
15. 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850-858.
16. 177Lulabeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11(19, suppl):7195s-7200s.
17. 177Lu-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-4601.
18. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25:540-547. (Pubitemid 350002961)
19. 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med. 2008;49:1066-1074.
20. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
21. Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 03, Revision-C.02. Wallingford, CT: Gaussian, Inc.; 2004.
22. 89Zr- DFO-trastuzumab. PLoS ONE. 2010;5:e8859.
23. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
24. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-739.
25. Kim JS, Lee JS, Im KC, et al. Performance measurement of the microPET Focus 120 scanner. J Nucl Med. 2007;48:1527-1535.
26. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003;44:1663-1670.
27. 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:1337-1345.
28. Börjesson PKE, Jauw YWS, Boellaard R, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-2140.
29. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.
30. 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008;35: 1857-1867.
31. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123-131.
32. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.
33. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
34. Meijs WE, Herscheid JDM, Haisma HJ, Pinedo HM. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int J Rad Appl Instrum A. 1992;43:1443-1447.
35. Meijs WE, Haisma HJ, Klok RP, et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med. 1997;38:112-118. (Pubitemid 27027011)
36. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-1319.